Basics to Brilliance: Haematology Podcast

Basics To Brilliance

Welcome to Basics to Brilliance, the podcast created to supplement & bolster your knowledge of Haematology.Featuring a two way, non-didactic conversational-style Q&A between the SpR and SHO, this podcast will be your pocket companion no matter where you are.We aim to cover: - Malignant and non-malignant topics - Science/lab detail - UK guidelines, hallmark trials and how these translate into clinical practice - Future research directions - The whole syllabus for FRCPath part 1 All readily accessible and completely free of charge!For every budding haematologist out there, we hope this podcast aids you in your endeavours and fills you with interest and excitement for the brilliant world of Haematology. Warmest Regards,Dr. EverdenDr. FaseyDr. Jafri Disclaimer: This podcast is intended as a revision aid and should not be used for the medical management of patients. Guidelines in the initial episodes span 2023/2024. We aim to update our content in accordance with the most recent available guidelines when possible.  This podcast is CPD accredited by the Royal College of Pathologists UK 

  1. Acquired Haemophilia A

    Jan 25

    Acquired Haemophilia A

    Feedback 00:52 Intro and chuckles 01:40 Case study: 75M, left calf swelling, put on DOAC, 24 hrs later haematoma and deep bleed on CT 06:00 General information Elderly (>65), Mortality 8-40%Common presentations: GI and UG bleeding, Retroperitoneal and muscle bleeds (compartment syndrome)Ptegnancy, TTP, Malignancy (15%), Autoimmune disease (17%)08:56 Pathogenesis and diagnosis: AutoAb against F8 *Bethesda units do not correlate with bleeding phenotype in Acquired HA- second orfer kinetics*HistoryAPTT, PT (isolated raised APTT)Mixing studies: 50/50 or 80/20 mixFactor Assays (**Intrinsic**)Decreased Factor VIII + Non-paralellism -> Bethesday Assay20:20 Non-clotting investigations 22:05 Treatment MDT + Comprehensive Care Center escalationRICE., TXA, Bypassing agentsLimit iatrogenic bleedingReview medicationsPregnancy: birth plan!!!  inhibitor can cross palcentaSteroid +/- Cyclophosphamide27:10 Bypassing Agents in Acquired Haemophilia A FENOC + EACH2 study: FEIBA vs NovoSeven = No difference in bleeding/thrombosis rates- more info at 33:25 for EACH2Obizor can be titrated according to response whereas FEIBA and NovoSeven cannotEmicizimab +/- Immunosuppression  = Not currently licesnsed in the UK 32:25 Inhibitor eradication Mean time to remission: 5 weeksGood prognostic markers: FVIII 1 or more, Inhibitor titre Steroids + Cyclophosphamide -> Steroids + Cyclo + RituximabBiggest cause of death: infection36:45 Follow up  Weekly FVIII levels and inhibitor monitoring till remission then monthly for 6 months then 2-3 monthly for a yearPlanned procedure; FVIII level38:45 Golden Nuggets 'Basics to Brilliance: Haematology Podcast' has been accredited for CPD credit by the Royal College of Pathologists UK.  Medical professionals and clinical scientists holding career-grade positions, who are registered with any of the Royal Colleges for CPD, will be eligible to earn 1 credit for every hour of learning.  Email: basicstobrilliancehaem@gmail.com Insta: BasicstoBrilliance X: @basics_2_brill Send us your feedback!

    42 min
  2. Haemophilia A in Pregnancy

    Jan 11

    Haemophilia A in Pregnancy

    Feedback 00:52 Intro - very important topic 02:00 Case Study: Haem/Obstetrics clinic, Family Hx Severe Haemophilia A, 12wks pregnant 04:15 Clotting changes in pregnancy Increased: FVII, FVIII, FX, VWF, FibrinogenDecreased: FXIII   Protein S, Antithrombin Stable: FIX07:57 New born to 6 months clotting: FVIII (8) similar to adultFIX (9) lower and rises after 6 months09:30 GUEST STARRING Dr. William Jones MRCP FRCA St6 Anaesthetics SpR with a special interest in Obstetrics 10:25 Will speaks about Delivery, Instrumentations,  Anaesthetics/Analgesia aspects of Obstetrics. 13:28 David asks about big needles, bleeding risks and Will explains Spinal vs Epidural 15:40 Three Stages of Labour (briefly, very briefly) *** ‘Haematologists advise active management of the third stage’ means: Management of process of delivering the placenta ie. Uterotonic - Syntometrine IM- helps reduce bleeding and get placenta outPlacental traction?Cord clampingThanks Will. 17:40 All the nuggets you'll need **avoiding a traumatic ICH to a baby boy** 1/ Pre-conception: baseline factor levels, family Hx (genetic mutations), discussion of treatments and risks   2/ Antenatal:  Male identification (IVF, fetal free DNA testing in maternal blood from 9 wks)Offer CVS (11-14 wks, miscarriage risk) or Amniocentesis (15-20 wks, pre-term delivery risk)Faetal anomaly scan @ 20wksCheck FVIII/FIX at booking, pre-procedure, 28wks and 34 wksMDT (haematologist, anaesthetist, obstetrician, nenonatolgist, lab) haemophilia centre, 24hr access to haenostasis labClear delivery plan by 37 weeks3/ Labour/deliver Avoid instrumentationRisk of bleeding: Forceps > Ventouse > Vaginal > C Section (high mortality for mother)FVIII >50 IU/dL : TXAFVIII 80 IU/dLAvoid faetal blood sampling, fetal scalp electrodes, ventouse, forceps, external cephalic version4/ Post partum Uncomplicated: maintain FVIII >50 for three daysComplicated/C-Section: maintain FVIII >50 for five daysContinue TXA till minimal Lochia If FVIII >50 needs VTEpNewborn: PT/APTT, FVIII and FIX (cord blood),Newborn: Routine screen for bleed with USS, Give factor if ANY suspicion of ICH- don't wait for a scan. CT/MRI head.Newborn: if ICH, maintain FVIII approx 80-100 for first 3 days, then above 50 for 2 weeks and will need prophylaxis going forwards. ?Vitamin K. SC vaccinations not IM. Give parent info. 40:15 David attempts the case study 44:20 How to write the delivery plan: A Practical Guide to the Management of the Fetus and Newborn With Hemophilia - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Suggested-Contents-of-the-Written-Delivery-Plana_tbl2_328606634 [accessed 10 Jan 2026] 47:20 Summary  'Basics to Brilliance: Haematology Podcast' has been accredited for CPD credit by the Royal College of Pathologists UK.  Medical professionals and clinical scientists holding career-grade positions, who are registered with any of the Royal Colleges for CPD, will be eligible to earn 1 credit for every hour of learning.  Email: basicstobrilliancehaem@gmail.com Insta: BasicstoBrilliance X: @basics_2_brill Send us your feedback!

    50 min
  3. 11/30/2025

    Haemophilia A: Inhibitors

    Feedback 00:52 Intro 02:10 Definition Common: Alloantibody neutralizes FVIIIRare: causes increased clearance of FVIII1/3 of Severe Haemophilia A patientsMedian time 10-15 emergency dosesRF: Mutation types (INSIGHT study), 60, African/Hispanic, HIVneg, large rFVIII doses, FVIII + inflammatory stimulus07:05 Inhibitor classifications Titres: Low (5 BU)Responder: Low vs HighTime: Dependent (FVIII inh.) vs Independent (FIX inh.)09:50 Presentation in practice Treatment failure, change in bleeding pattern, anaphylaxisScreening: prior to invasive procedures, before/after treatment changesRoutine surveillance:Mild- moderate: Yearly + 2-3 wks after emergency treatmentSevere: Every 3rd emergency dose or 3 monthly13:55 Tests (needs repeat) Mixing studyFVIII assay (48 hours post dose)Bethesda assay (if 80-100% residual FVIII = no inhibitor)Specialist: ELISA, In-vivo recoveryMost sensitive: FVIII half-life studiesInhibitor Assays (Bovine chromogenic assay)19:45 Preventative measures? Mild to moderate: DDAVP when possibleSevere: prophylaxis 23:40 Treatments Bypass agent: skips intrinsic pathway, straight to extrinsic F.I.B.A: activated PCC (II, VIII, IX, X)Onset 15-30 minsDose: 50-100IU/kgHalf life 8-12 hrsNB: Plasma derived: FVIII contamination, infectionContraindicated: EmicizimabNovoSeven: activated rFVIIaPeak 15 minsDose: 270ug/kg, fixed dose, can’t titrateNB: Half life 2 hours, can’t titrateObizor: Porcine rVIIIPeak 30 minsDose: 200IU/kg and titrateablePorcine Bethesda before use34:35 Prophylaxis EmicizumabImmune tolerance induction pts: Emicizumab, NovoSeven > FIBABreakthrough bleeding: increase frequency38:22 Immune Tolerance Induction: start ASAP if inhibitor present UKHCDO: Long term FVIII tolerance induction and maintenance is key for severe Haemophilia A - don't rely on Emicizumab Success rate: 70%, consistent treatment, fewer emergency doses prior to starting, Historic peak titre 500 BU titres46:20 International Immune Tolerance Study (Hay, DiMichele)- Blood 2012 47:50 Monitoring and Response Assessment  Success: FVIII half-life  >7 hours BU negativeMeasurable trough levels at 48 hoursFailure: escalated to max rFVIII but still uptrending titres or fall of 20% in 6 months (alternative systemic agents)NB: rule out intercurrent infection50:33  VerITI-8 trial  51:28 Golden Nuggets 'Basics to Brilliance: Haematology Podcast' has been accredited for CPD credit by the Royal College of Pathologists UK.  Medical professionals and clinical scientists holding career-grade positions, who are registered with any of the Royal Colleges for CPD, will be eligible to earn 1 credit for every hour of learning.  Email: basicstobrilliancehaem@gmail.com Insta: BasicstoBrilliance X: @basics_2_brill Send us your feedback!

    54 min

Ratings & Reviews

5
out of 5
2 Ratings

About

Welcome to Basics to Brilliance, the podcast created to supplement & bolster your knowledge of Haematology.Featuring a two way, non-didactic conversational-style Q&A between the SpR and SHO, this podcast will be your pocket companion no matter where you are.We aim to cover: - Malignant and non-malignant topics - Science/lab detail - UK guidelines, hallmark trials and how these translate into clinical practice - Future research directions - The whole syllabus for FRCPath part 1 All readily accessible and completely free of charge!For every budding haematologist out there, we hope this podcast aids you in your endeavours and fills you with interest and excitement for the brilliant world of Haematology. Warmest Regards,Dr. EverdenDr. FaseyDr. Jafri Disclaimer: This podcast is intended as a revision aid and should not be used for the medical management of patients. Guidelines in the initial episodes span 2023/2024. We aim to update our content in accordance with the most recent available guidelines when possible.  This podcast is CPD accredited by the Royal College of Pathologists UK 

You Might Also Like